BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Paratek Pharmaceuticals, Inc. 

75 Kneeland Street

Boston  Massachusetts  02111  U.S.A.
Phone: 617-275-0040 Fax: 617-275-0039


View Clinical Trials from BioPharm Insight

Paratek Pharmaceuticals, Inc. is a private biopharmaceuticals company engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases. Paratek has a particular focus on developing new therapeutics for the infectious disease market to combat the problem of antibiotic resistance. Paratek was founded in 1996 by Dr. Stuart B. Levy, the world-renowned expert in antibiotic resistance and Professor of Molecular Biology and Microbiology and of Medicine at Tufts University School of Medicine, and by Dr. Walter Gilbert, the successful biotechnology entrepreneur and well-known Nobel Prize-winning Professor at Harvard University. Paratek was created to harness the 30+ years of research and discovery in mechanisms of antibiotic resistance and tetracycline chemistry by Dr. Levy and his scientific team at Tufts University School of Medicine.

Paratek has established two product development programs to identify and develop multiple products for the treatment of infectious diseases:

  • The Tetracycline Resistance Project (Tet Project), based on expertise in medicinal chemistry
  • The Multiple Antibiotic Resistance Project (Mar Project), based on novel discoveries in pathogen genomics

Senior Management:
Thomas J. Bigger, President & Chief Executive Officer
Stuart B. Levy, M.D., Chief Scientific Officer
Beverly A. Armstrong, Vice President & Chief Financial Officer
George C. Hillman, Executive Vice President & Chief Operating Officer
S. Ken Tanaka, Vice President of Research & Development
Dennis Molnar, Executive Director of Corporate Development

Board of Directors
Walter Gilbert, Ph.D., Chairman
Stuart B. Levy, M.D., Vice Chairman & CSO
Thomas J. Bigger, President & CEO, Director
Kalevi Kurkijarvi, Ph.D., Director
Kenneth J. Novack, Director
Sir Mark Richmond, Ph.D., Director
Patricia Smith, M.D., Director
Pieter Strijkert, Ph.D., Director

Last Updated: 04-23-02

 Key Statistics

Ownership: Private

Web Site: Paratek Pharmaceuticals, Inc.
Employees: 76

 Company News
Paratek Pharmaceuticals, Inc. Reports First Quarter 2015 Financial and Operating Results 5/17/2015 4:45:46 PM
Paratek Pharmaceuticals, Inc. Announces Closing Of Common Stock Offering 5/6/2015 7:28:54 AM
Paratek Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of 2,860,000 Shares Of Common Stock 4/30/2015 7:39:01 AM
Paratek Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock 4/28/2015 7:45:59 AM
Paratek Pharmaceuticals, Inc. Reports Full Year 2014 Financial And Operating Results 4/2/2015 8:02:38 AM
Paratek Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences 3/12/2015 7:49:44 AM
Paratek Pharmaceuticals, Inc. To Present At The Cowen and Company Healthcare Conference 2/23/2015 7:45:15 AM
Paratek Pharmaceuticals, Inc. To Present At The Leerink Global Healthcare Conference 2/10/2015 8:03:13 AM
Paratek Pharmaceuticals, Inc. Adopts Inducement Equity Incentive Plan Under NASDAQ Listing Rule 5635(c)(4) 2/10/2015 7:51:00 AM
Paratek Pharmaceuticals, Inc. To Receive $4 Million Payment From Actavis (ACT) With Initiation Of Phase 3 Trial Of Sarecycline 1/6/2015 7:19:19 AM